Medtronic to Buy CathWorks for Up to $585M, Adding AI-Driven FFRangio System
Medtronic will acquire CathWorks for up to $585 million, gaining exclusive rights to its AI-powered FFRangio coronary physiology assessment system following their 2022 co-promotion agreement. The acquisition, pending FTC clearance and expected by end of fiscal 2026, is projected to be neutral to accretive to adjusted EPS beyond FY2027.
1. Medtronic Announces Acquisition of CathWorks
Medtronic announced it will acquire Israel-based CathWorks in a deal valued at up to $585 million, plus potential earn-out payments. The transaction follows a strategic partnership initiated in 2022 around the CathWorks FFRangio System, an AI-driven angiography solution for assessing coronary physiology. Closing is expected by the end of Medtronic’s fiscal 2026, pending clearance from the U.S. Federal Trade Commission, after which CathWorks will operate within Medtronic’s cardiovascular portfolio.
2. Financial Implications for Medtronic
Management expects the acquisition to be immaterial to fiscal 2027 GAAP and adjusted earnings per share, turning neutral to slightly accretive thereafter. The deal leverages CathWorks’ FFRangio System, which provides full-tree fractional flow reserve measurements and intraprocedural optimization tools, and preserves cash flow projections by incorporating structured earn-outs tied to post-closing performance milestones.
3. Strategic Rationale and Market Impact
By integrating CathWorks’ AI-powered physiology platform, Medtronic aims to strengthen its interventional cardiology offering and reduce unnecessary percutaneous coronary interventions. The move aligns with the company’s broader strategy to expand its digital health capabilities and address growing demand for precision diagnostics. Analysts note the deal complements recent product launches and underscores Medtronic’s commitment to leveraging advanced computational science to drive clinical outcomes and long-term revenue growth.